Greenstone uses stem cells for Duchenne heart disease

Greenstone Biosciences received NIH funding to develop drugs for Duchenne muscular dystrophy (DMD) cardiomyopathy. They're using human induced pluripotent stem cells (iPSCs) and AI to find treatments, aiming to bypass the high failure rate of animal models in human trials. This could mean better drug candidates for Duchenne patients and a new approach for other heart conditions.